Name | Number of supported studies | Average coverage | |
---|---|---|---|
mesothelial cell | 3 studies | 32% ± 11% |
Insufficient scRNA-seq data for expression of RSPO1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 98% | 866.68 | 240 / 245 | 68% | 1.90 | 343 / 502 |
ovary | 71% | 252.79 | 128 / 180 | 84% | 34.46 | 361 / 430 |
uterus | 100% | 4791.45 | 170 / 170 | 27% | 1.49 | 125 / 459 |
breast | 73% | 377.22 | 334 / 459 | 48% | 3.13 | 539 / 1118 |
lung | 95% | 518.71 | 549 / 578 | 16% | 0.68 | 184 / 1155 |
intestine | 77% | 248.96 | 739 / 966 | 9% | 0.20 | 48 / 527 |
skin | 80% | 545.44 | 1439 / 1809 | 6% | 0.16 | 27 / 472 |
esophagus | 78% | 210.96 | 1127 / 1445 | 5% | 0.11 | 9 / 183 |
stomach | 63% | 445.14 | 225 / 359 | 20% | 0.65 | 56 / 286 |
bladder | 62% | 178.76 | 13 / 21 | 7% | 0.15 | 33 / 504 |
adipose | 63% | 718.72 | 758 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 58% | 392.47 | 774 / 1335 | 0% | 0 | 0 / 0 |
pancreas | 9% | 11.64 | 30 / 328 | 34% | 1.16 | 60 / 178 |
tonsil | 0% | 0 | 0 / 0 | 31% | 0.67 | 14 / 45 |
lymph node | 0% | 0 | 0 / 0 | 31% | 0.78 | 9 / 29 |
spleen | 28% | 79.01 | 67 / 241 | 0% | 0 | 0 / 0 |
kidney | 26% | 71.85 | 23 / 89 | 1% | 0.03 | 10 / 901 |
thymus | 1% | 1.20 | 6 / 653 | 21% | 1.69 | 129 / 605 |
adrenal gland | 1% | 2.42 | 3 / 258 | 17% | 3.53 | 38 / 230 |
heart | 10% | 30.33 | 87 / 861 | 0% | 0 | 0 / 0 |
brain | 2% | 2.81 | 58 / 2642 | 1% | 0.07 | 5 / 705 |
liver | 0% | 1.09 | 1 / 226 | 2% | 0.04 | 7 / 406 |
peripheral blood | 1% | 1.10 | 5 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0016055 | Biological process | Wnt signaling pathway |
GO_0090263 | Biological process | positive regulation of canonical Wnt signaling pathway |
GO_0002090 | Biological process | regulation of receptor internalization |
GO_0001934 | Biological process | positive regulation of protein phosphorylation |
GO_0030177 | Biological process | positive regulation of Wnt signaling pathway |
GO_0005576 | Cellular component | extracellular region |
GO_0005634 | Cellular component | nucleus |
GO_0008201 | Molecular function | heparin binding |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0005515 | Molecular function | protein binding |
GO_0001664 | Molecular function | G protein-coupled receptor binding |
Gene name | RSPO1 |
Protein name | R-spondin-1 (Roof plate-specific spondin-1) (hRspo1) |
Synonyms | |
Description | FUNCTION: Activator of the canonical Wnt signaling pathway by acting as a ligand for LGR4-6 receptors . Upon binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 associate with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. Also regulates the canonical Wnt/beta-catenin-dependent pathway and non-canonical Wnt signaling by acting as an inhibitor of ZNRF3, an important regulator of the Wnt signaling pathway. Acts as a ligand for frizzled FZD8 and LRP6. May negatively regulate the TGF-beta pathway. Has a essential roles in ovary determination. Regulates Wnt signaling by antagonizing DKK1/KREM1-mediated internalization of LRP6 through an interaction with KREM1 . . |
Accessions | ENST00000615459.4 [Q2MKA7-2] ENST00000612451.4 [Q2MKA7-3] ENST00000356545.7 [Q2MKA7-1] ENST00000401068.1 [Q2MKA7-1] Q2MKA7 |